Company Profile

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
All Other Miscellaneous Food Manufacturing (311999)

SIC:
Food Preparations, Not Elsewhere Classified (2099)

Contact Information

Investor Relations
IR contact
T: 250-765-6424 ext. 202
IR@lexariabioscience.com

Company Contact
Lexaria Bioscience Corp.
740 McCurdy Road
Suite 100
Kelowna, BC V1X 2P7
Canada